Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (11): 2393-2394.doi: 10.4103/1673-5374.371358

Previous Articles     Next Articles

Targeting glial metabolism in neurodegenerative diseases: detail matters

Ruqayya Afridi, Kyoungho Suk*   

  1. Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, South Korea (Afridi R, Suk K) 
    Department of Biomedical Sciences, BK21 PLUS KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu, South Korea (Afridi R, Suk K) 
    Brain Science and Engineering Institute, Kyungpook National University, Daegu, South Korea (Afridi R, Suk K) 
  • Online:2023-11-15 Published:2023-05-04
  • Contact: Kyoungho Suk, PhD, ksuk@knu.ac.kr.
  • Supported by:
    This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2017R1A5A2015391, 2020M3E5D9079764) (to KS).

PDF

51

Abstract: Neurodegenerative diseases, a group of disorders associated with advanced age, are typified by the disease-specific accumulation of mutant proteins and neuroinflammation. For decades, treatment modalities for these disorders have focused on addressing neuronal malfunction, which has resulted in the failure of therapies. Recent studies have identified the crucial role of glial cells in exacerbating neurodegenerative processes via the release of neuroinflammatory mediators. Glia, the major immune component of the central nervous system (CNS), undergo numerous phenotypic transitions and regulate the outcomes of various pathologies (Afridi et al., 2022).